Novo Nordisk A/S (NYSE:NVO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Novo Nordisk A/S (NYSE:NVO) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $144.50.

Several equities research analysts have issued reports on NVO shares. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th.

Novo Nordisk A/S Stock Performance

NVO opened at $99.82 on Tuesday. The stock’s 50 day simple moving average is $117.94 and its 200-day simple moving average is $129.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $447.95 billion, a PE ratio of 32.30, a P/E/G ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.

Institutional Trading of Novo Nordisk A/S

Several large investors have recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S during the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $28,000. Finally, Halpern Financial Inc. raised its position in shares of Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.